Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Adolescent
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antirheumatic Agents
/ therapeutic use
Arthritis, Juvenile
/ drug therapy
Child
Child, Preschool
Germany
Humans
Infant
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Interleukin-1beta
/ antagonists & inhibitors
Registries
Retrospective Studies
Young Adult
Anakinra
Autoinflammatory disease
Canakinumab
Interleukin-1
Proinflammatory cytokines
Systemic juvenile idiopathic arthritis
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
22 Mar 2021
22 Mar 2021
Historique:
received:
23
05
2020
accepted:
24
02
2021
entrez:
23
3
2021
pubmed:
24
3
2021
medline:
5
11
2021
Statut:
epublish
Résumé
Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with dysregulation of the innate immune system driven by cytokines. A major role is ascribed to interleukin-1β (IL-1β), supporting the autoinflammatory character of the disease and offering an effective blocking mechanism for treatment. Here we present clinical practice data from the German AID-registry for patients treated with IL-1 inhibition (IL-1i). In 2009 a clinical and research consortium (AID-Net) was established, including an online AID-registry. Patients with documented sJIA diagnosis were identified. Data for this retrospective IL-1i study were recorded by 17 centers. Response to treatment was evaluated according to Wallace criteria and additionally by an own classifying clinical response system. In 6 years, 202 patients with confirmed sJIA were recorded in the AID-registry. Out of these, 111 children received therapy with Anakinra (ANA) (n = 84, 39 f) and/or Canakinumab (CANA) (n = 27, 15 f) at a median age of 8.7 y (range 0.6-19.1). During the first 12 months 75/111 (ANA 55, CANA 20) patients were evaluated according to Wallace criteria (achievement of inactive disease 28/55 and 17/20, remission over 6 months under medication 13/55 and 7/20 cases). Over the whole period of time, clinical response was preserved in the majority of patients (ANA 54/80, CANA 20/27). Arthritis mostly persisted in polyarticular (PA) courses. During treatment with IL-1i concomitant medication could be tapered in about 15%. IL-1i was discontinued in 59/111 patients. 45 (15) adverse events (AE)s in ANA (CANA) treated patients (19.7 (26.6) AE/100 ANA (CANA) exposure years, 95%CI: 14.4-26.4 (14.9-43.9)) were reported. In a large cohort of sJIA patients from Germany, we can confirm an overall favorable clinical response to both available IL-1 blocking agents. IL-1i was well tolerated with acceptable safety and effectiveness in a real-life clinical setting.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with dysregulation of the innate immune system driven by cytokines. A major role is ascribed to interleukin-1β (IL-1β), supporting the autoinflammatory character of the disease and offering an effective blocking mechanism for treatment. Here we present clinical practice data from the German AID-registry for patients treated with IL-1 inhibition (IL-1i).
METHODS
METHODS
In 2009 a clinical and research consortium (AID-Net) was established, including an online AID-registry. Patients with documented sJIA diagnosis were identified. Data for this retrospective IL-1i study were recorded by 17 centers. Response to treatment was evaluated according to Wallace criteria and additionally by an own classifying clinical response system.
RESULTS
RESULTS
In 6 years, 202 patients with confirmed sJIA were recorded in the AID-registry. Out of these, 111 children received therapy with Anakinra (ANA) (n = 84, 39 f) and/or Canakinumab (CANA) (n = 27, 15 f) at a median age of 8.7 y (range 0.6-19.1). During the first 12 months 75/111 (ANA 55, CANA 20) patients were evaluated according to Wallace criteria (achievement of inactive disease 28/55 and 17/20, remission over 6 months under medication 13/55 and 7/20 cases). Over the whole period of time, clinical response was preserved in the majority of patients (ANA 54/80, CANA 20/27). Arthritis mostly persisted in polyarticular (PA) courses. During treatment with IL-1i concomitant medication could be tapered in about 15%. IL-1i was discontinued in 59/111 patients. 45 (15) adverse events (AE)s in ANA (CANA) treated patients (19.7 (26.6) AE/100 ANA (CANA) exposure years, 95%CI: 14.4-26.4 (14.9-43.9)) were reported.
CONCLUSION
CONCLUSIONS
In a large cohort of sJIA patients from Germany, we can confirm an overall favorable clinical response to both available IL-1 blocking agents. IL-1i was well tolerated with acceptable safety and effectiveness in a real-life clinical setting.
Identifiants
pubmed: 33752669
doi: 10.1186/s12969-021-00510-8
pii: 10.1186/s12969-021-00510-8
pmc: PMC7986520
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1beta
0
canakinumab
37CQ2C7X93
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Références
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Clin Rheumatol. 2018 Aug;37(8):2233-2240
pubmed: 29770930
Arthritis Rheum. 2011 Feb;63(2):545-55
pubmed: 21280009
Arthritis Rheum. 2008 May;58(5):1505-15
pubmed: 18438814
J Rheumatol. 2004 Nov;31(11):2290-4
pubmed: 15517647
Ann Rheum Dis. 2011 May;70(5):747-54
pubmed: 21173013
Clin Trials. 2018 Jun;15(3):268-277
pubmed: 29542334
Pediatr Rheumatol Online J. 2014 Jul 16;12:28
pubmed: 25114627
Rheumatology (Oxford). 2011 Jan;50(1):237-42
pubmed: 21148158
N Engl J Med. 2012 Dec 20;367(25):2396-406
pubmed: 23252526
J Rheumatol. 1992 Mar;19(3):424-30
pubmed: 1578458
J Rheumatol. 2019 Feb;46(2):190-197
pubmed: 30275259
J Exp Med. 2005 May 2;201(9):1479-86
pubmed: 15851489
Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7
pubmed: 29357887
Drug Des Devel Ther. 2018 Jun 08;12:1633-1643
pubmed: 29922038
Arthritis Rheumatol. 2019 Jul;71(7):1163-1173
pubmed: 30848528
Ann Rheum Dis. 2018 Dec;77(12):1710-1719
pubmed: 30269054
Arthritis Rheumatol. 2016 Dec;68(12):3023-3034
pubmed: 27332999
Clin Immunol. 2015 Jul;159(1):72-83
pubmed: 25956529
Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10
pubmed: 22290637
Arthritis Rheumatol. 2016 Jan;68(1):218-28
pubmed: 26314396
Arthritis Res Ther. 2017 Nov 22;19(1):256
pubmed: 29166924
J Rheumatol. 2019 Apr;46(4):416-421
pubmed: 30647180
Adolesc Health Med Ther. 2017 Nov 09;8:125-135
pubmed: 29184458
Clin Immunol. 2012 Feb;142(2):176-93
pubmed: 22154868
Indian J Pediatr. 2019 Jul;86(7):576-577
pubmed: 31154576
Arthritis Rheumatol. 2019 Jul;71(7):1030-1033
pubmed: 30802004
N Engl J Med. 2012 Dec 20;367(25):2385-95
pubmed: 23252525
Pediatr Rheumatol Online J. 2012 Nov 23;10(1):40
pubmed: 23176399
Orphanet J Rare Dis. 2015 Feb 15;10:19
pubmed: 25758134
Arthritis Rheumatol. 2016 Dec;68(12):3010-3022
pubmed: 27333294
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22
pubmed: 29622022
Arthritis Rheum. 2012 Feb;64(2):557-67
pubmed: 21953497
Rheumatology (Oxford). 2016 Apr;55(4):669-79
pubmed: 26628580
Z Rheumatol. 2020 Sep;79(7):639-648
pubmed: 32253510
Arthritis Rheum. 2006 May;54(5):1595-601
pubmed: 16645998
RMD Open. 2015 Apr 30;1(1):e000036
pubmed: 26509061
Arthritis Rheumatol. 2014 Apr;66(4):1034-43
pubmed: 24757154